Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
Shots:
- The US FDA has approved Jylamvo (methotrexate) to treat pediatric with acute lymphoblastic leukemia (ALL) & polyarticular juvenile idiopathic arthritis (pJIA)
- Jylamvo is an oral solution (orange-flavored) of methotrexate, suitable for both adults and pediatric. It's used to treat various conditions, including rheumatological, dermatological, and oncological diseases
- Jylamvo was approved for treating adults with various conditions, including ALL, mycosis fungoides, r/r non-Hodgkin lymphoma, rheumatoid arthritis, and severe psoriasis
Ref: Businesswire | Image: Shorla Oncology
Related News:- Shorla Oncology Reports the Acquisition of Jylamvo from Therakind Targeting Oncology and Autoimmune Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
